Precision BioSciences Provides Update on Allogeneic CAR T Pr

Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T... | May 31, 2023

Related Keywords

Michael Amoroso , Precision Biosciences Inc , Nasdaq , Drug Administration , Precision Biosciences , Chief Executive Officer , Potential First In Class Allogeneic , Product Candidate , Dose Level , Alan List , Chief Medical Officer , Stealth Cell , Potential Best In Class Allogeneic , Earlier Line , Hosted Webcast , Conference Call , Private Securities Litigation Reform Act , Quarterly Report , Nc Stock Exchange , News , Information , Press Release , Safety , Profile , Gas , Ignificantly , Mproved , Ompared , O , Rior , Cohorts , N , Patients , Hosed , Sing , Optimized , Product , It , Tower , Intensity , Rade , , Dr , Greater , Allogeneic , Ar Dtil Us74019p1084 ,